Mexico Oral Anti-Diabetic Drug Market Size, Share, and COVID-19 Impact Analysis, By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides), By End Users (Hospitals, Homecare, Specialty Centers, and Others), and Mexico Oral Anti-Diabetic Drug Market Insights, Industry Trend, Forecasts to 2033

Mexico Oral Anti-Diabetic Drug Market Insights Forecasts to 2033

• The Mexico Oral Anti-Diabetic Drug Market Size was estimated at USD 1.43 Billion in 2023.
• The Market is Growing at a CAGR of 3.46% from 2023 to 2033
• The Mexico Oral Anti-Diabetic Drug Market Size is Expected to Reach USD 2.01 Billion by 2033

The Mexico Oral Anti-Diabetic Drug Market is Expected to Reach USD 2.01 billion by 2033, growing at a CAGR of 3.46% from 2023 to 2033.

Market Overview

The oral anti-diabetic drug market in Mexico is the area of the Mexican pharmaceutical industry dedicated to the development, production, promotion, and distribution of oral drugs for the treatment and management of diabetes mellitus. These oral drugs are intended to help people with diabetes, especially those with Type 2 diabetes and prediabetes, control their blood glucose levels. The rising incidence of diabetes and continuous improvements in pharmaceutical research and development have propelled the market for oral anti-diabetic medications to tremendous expansion and change in recent years. This market is essential for offering treatment options that meet the various needs of diabetic patients as the demand for efficient diabetes management is growing. In addition, the rising prevalence of diabetes is caused by several factors, including sedentary lifestyles, poor eating habits, and an aging population. Additionally, the market for oral antidiabetic medications is expected to increase favorably as a result of the increasing usage of artificial sweeteners, such as aspartame, in food products as a sugar alternative. Furthermore, the government is actively supporting diabetes prevention initiatives to lower the prevalence of the condition and increase access to oral anti-diabetic drugs.

Report Coverage

This research report categorizes the market for the Mexico oral anti-diabetic drug market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Mexico oral anti-diabetic drug market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Mexico oral anti-diabetic drug market.

Driving Factors

The Mexico oral anti-diabetic drug market is driven by continuous improvements in pharmaceutical research & development as well as the rising incidence of diabetes. This market is essential for offering treatment alternatives that meet the various needs of diabetic patients, as the necessity for efficient diabetes management is growing. The rising incidence of diabetes broadly is one of the main factors driving the market for oral anti-diabetic medications. In addition, the market's demand is anticipated to be fueled by shifting lifestyles and the consumption of fast food, which has led to a high prevalence of obesity. The market for oral antidiabetic medications is anticipated to grow due to the large number of participants.

Restraining Factors

The use of oral diabetes drugs can cause several adverse effects, such as diarrhea, bloating, gas, nausea, upset stomach, and vitamin B12. This hinders the market. Furthermore, the market expansion is slowed by the costly treatment alternatives.

Market Segmentation

The Mexico oral anti-diabetic drug market share is classified into the drugs and end users.

• The sulfonylureas equipment segment accounted for the largest share in 2023 and is estimated to grow at a significant CAGR during the projected period.

Based on the drugs, the Mexico oral anti-diabetic drug market is divided into biguanides, alpha-glucosidase inhibitors, dopamine -d2 receptor agonist, sodium-glucose cotransport -2 (sglt-2) inhibitor, dipeptidyl peptidase - 4 (dpp-4) inhibitors, sulfonylureas, and meglitinides. Among these, the sulfonylureas equipment segment accounted for the largest share in 2023 and is estimated to grow at a significant CAGR during the projected period. This segment is growing because it is inexpensive and widely used. These medications, which increase the production of insulin, remain the mainstay of treatment for Type 2 diabetes. The rising prevalence of diabetes, government health programs, and the growing need for affordable treatments are all predicted to propel the segment's growth at a substantial compound annual growth rate.

• The specialty centers segment accounted for a significant market share in 2023 and is estimated to grow at a significant CAGR during the projected period.

Based on the end users, the Mexico oral anti-diabetic drug market is classified into hospitals, homecare, specialty centers, and others. Among these, the specialty centers segment accounted for a significant market share in 2023 and is estimated to grow at a significant CAGR during the projected period. The segment is anticipated to grow due to the growing demand for individualized healthcare services and easier access to cutting-edge diabetes medications. This growth is driven by government initiatives to expand diabetes management facilities, improvements in treatment protocols, and increased patient preference for specialized diabetes care.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Mexico oral anti-diabetic drug market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda
• Novo Nordisk
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Astellas
• Boehringer Ingelheim
• Merck And Co.
• AstraZeneca
• Bristol Myers Squibb
• Novartis
• Sanofi
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Mexico, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Mexico oral anti-diabetic drug market based on the below-mentioned segments

Mexico Oral Anti-Diabetic Drug Market, By Drugs  

• Biguanides
• Alpha-glucosidase inhibitors
• Dopamine -D2 Receptor Agonist
• Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
• Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
• Sulfonylureas
• Meglitinides

Mexico Oral Anti-Diabetic Drug Market, By End Users

• Hospitals
• Homecare
• Specialty Centers
• Others